Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases

Respiratory System Clinical Trial

Official title:

Non-blinded, Single Dose, Single Centre Trial to Assess the Pulmonary Deposition as Well as Pharmacokinetics, Safety and Tolerability of 99mTc Labeled Ciprofloxacin When Delivered as a Single Dose From a Dry Powder Inhaler to Healthy Subjects With and Without Charcoal Block and Patients Suffering From Bronchiectasis and COPD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01538667
• Other study ID #: 11523
• Secondary ID: 2011-000342-38
• Status: Completed
• Phase: Phase 1
• First received: February 21, 2012
• Last updated: August 20, 2014
• Start date: April 2012
• Est. completion date: July 2012

Study information

• Verified date: August 2014
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to characterize variability and extent of the deposition of ciprofloxacin in the respiratory tract of healthy subjects in comparison to patients with chronic lung diseases after inhalation of a single 50 mg dry powder dose containing 32 mg active substance. In addition the safety and pharmacokinetics of ciprofloxacin will be evaluated. In this study the radiolabeled substance will be administered and scintigraphy imaging techniques will be used to demonstrate the lung deposition visually. In the healthy subjects an additional pharmacokinetic method is used to calculate lung deposition indirectly based on pharmacokinetic data derived from plasma. For this purpose they will inhale at a separate occasion another dose of ciprofloxacin after having ingested activated charcoal. The latter serves to bind ciprofloxacin which is swallowed down during the inhalation maneuver in the gastrointestinal (GI) tract, thus preventing its uptake into the blood (charcoal block). Safety investigations will focus on local tolerability in the lung.

Pharmacokinetics is to see how the body absorbs, distributes, breaks down and gets rid of the study drug.

Results from this study will be used to show how the drug is distributed in the human lung.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: July 2012
• Est. primary completion date: July 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Inclusion criteria for all subjects:

• Understanding of the study and written informed consent prior to any study-related procedures

• Additional inclusion criteria for healthy subjects:

• Age: 18 to 65 years (inclusive) at screening visit

• Males

• Non- or ex-smokers who smoked < 5 pack-years and stopped smoking > 1 year prior to screening visit

• Results of laboratory tests within the normal ranges; minor deviations are acceptable provided that they are not judged clinically significant by the investigator

• Additional inclusion criteria for patients with COPD (chronic obstructive pulmonary disease):

• Age: 40 to 70 years (inclusive) at screening visit

• Males and females

• All patients must have a diagnosis of COPD of Stage II or III according to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) Classification (post-bronchodilator forced expiratory volume in 1 second (FEV1): 80% > FEV1 = 30% of predicted values and a post-bronchodilator FEV1/FVC = 70% (FVC = forced vital capacity)

• Minimum smoking history of 10 pack-years

• Additional inclusion criteria for patients with bronchiectasis:

• Age: 18 to 75 years (inclusive) at screening visit

• Males and females

• Diagnosis of bronchiectasis

Exclusion Criteria:

• Known hypersensitivity, allergy or intolerance to study drug formulation ingredients

• Febrile illness within 1 week prior to screening visit

• Concomitant severe diseases (judged by the investigator) or diseases which are contraindications for the use of inhaled ciprofloxacin

• Use of ciprofloxacin within 30 days before screening visit

• Use of systemic or topical medicines or substances which oppose the study objectives or which might influence them, e.g. systemic administration of antibiotics which are subject to renal excretion (e.g. beta-lactam antibiotics, levofloxacin, ofloxacin, etc.), furosemide and antacids

• Donation of more than 450 mL of blood within 4 weeks before screening visit

• Clinically relevant findings in the ECG

• Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical investigation

• Participation in another clinical study less than 8 weeks prior to screening visit

• Pulmonary exacerbation within the 6 weeks prior to screening

• History of lung transplant or any lung surgery or on any thoracic surgery waiting list

• Additional exclusion criteria for healthy subjects

• Lung function measurements outside normal limits (Normal values: FEV1/FVC > 70% and FEV1 and FVC > 80% of predicted)

• Additional exclusion criteria for patients

• Regular use of daytime oxygen therapy

• Diagnosis of bronchial asthma

• Diagnosis of clinically evident bronchiectasis (COPD patients)

• Total blood eosinophil count >/= 600/mm3.

• Completion of a pulmonary rehabilitation program in the six weeks prior to screening visit or current participation in a pulmonary rehabilitation program

• Change in dose or type of any medications within 4 weeks prior to the screening visit

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Respiratory System

Intervention

Drug:
• Ciprofloxacin (Cipro Inhale, BAYQ3939)
50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects
• Ciprofloxacin (Cipro Inhale, BAYQ3939)
50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block
• Ciprofloxacin (Cipro Inhale, BAYQ3939)
50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients
• Ciprofloxacin (Cipro Inhale, BAYQ3939)
50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ciprofloxacin pharmacokinetics including lung deposition	Firstly, scintigraphic imaging, a non-invasive method using a radioactive (99mTc-) label tagged to the formulation, will be used to describe the distribution and deposition of a single inhaled dose of Ciprofloxacin Dry Powder Inhalation (DPI) in the lung quantitatively. Secondly, based on blood sampling over a period of 24 hours after inhalation non-compartmental pharmacokinetic parameters of ciprofloxacin will be calculated to determine the systemic exposure to drug following inhalation of a single 32.5 mg Ciprofloxacin dose.	Within 24 hours after treatment	No
Secondary	Adverse Events collection		Within 30 days	Yes

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
•   Click here to find results for studies related to Bayer Healthcare products.